Scholarlink

Introduction <p>Despite improvement in treatment, rheumatoid arthritis (RA) management remains inconsistent.</p> Aims <p>To evaluate the worldwide disparities in the use of biological and targeted molecules (advanced) RA therapies, focusing on differences across continents and socioeconomic strata, and to identify factors associated with their utilisation.</p> Methods <p>Cross-sectional analysis of the international COVAD-2 cohort, including demographics, socioeconomic factors, disease characteristics, patient-reported outcomes, and treatments. Primary outcomes assessed treatment distribution by continent, secondary outcomes evaluated distribution by Human Development Index (HDI), with predictors analysed using multivariable logistic regression.</p> Results <p>At the time of analysis, COVAD2 included 10,739 participants; 2007 had RA, 1997 with geographical data included in this study (mean age 50.9&#xa0;years, 88.1% women). Most patients came from Europe (39.4%) and Asia (24.8%); 61.3% and 23.7% were from very high- and high-HDI countries, respectively. Overall, 29.6% of patients used advanced therapies, with the highest rate in Europe (44.0%), followed by North America and Oceania (33.9%), South America (31.1%), Asia (11.7%), and Africa (5.3%) (<i>p</i> &lt; 0.001). Usage correlated strongly with HDI: 2.7% in low-HDI to 38.8% in very-high-HDI countries (Compared to very-high income, Odds Ratio for high 0.561 (95% CI 0.403;0.782), for medium 0.288 (95% CI 0.153;0.539), and for low income 0.275 (95% CI 0.034;2.199); <i>p</i> &lt; 0.001). Regions with limited access relied more on glucocorticoids. Disparities across continents and HDI categories remained after adjusting for confounders(demographic characteristics, disease activity, comorbidities, and patient-reported outcomes.</p> Conclusion <p>Marked continent- and HDI-based inequities in biologic and targeted DMARD use persist globally, demanding coordinated action from the rheumatology community to ensure equitable RA care across resource settings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Global inequities in biologic and targeted DMARD use in rheumatoid arthritis: cross-sectional data from the international COVAD-2 cohort

  • 期刊论文

  • 发表日期：

    2026年5月13日

查看全文
  • Nelly Ziade,
  • Ihsane Hmamouchi,
  • Marc Moussallem,
  • Bendy Lemon Salameh,
  • Praggya Yaadav,
  • Ashima Makol,
  • Marcin Milchert,
  • Tsvetelina Velikova,
  • Ioannis Parodis,
  • Elena Nikiphorou,
  • Vikas Agarwal,
  • Latika Gupta

摘要

Introduction

Despite improvement in treatment, rheumatoid arthritis (RA) management remains inconsistent.

Aims

To evaluate the worldwide disparities in the use of biological and targeted molecules (advanced) RA therapies, focusing on differences across continents and socioeconomic strata, and to identify factors associated with their utilisation.

Methods

Cross-sectional analysis of the international COVAD-2 cohort, including demographics, socioeconomic factors, disease characteristics, patient-reported outcomes, and treatments. Primary outcomes assessed treatment distribution by continent, secondary outcomes evaluated distribution by Human Development Index (HDI), with predictors analysed using multivariable logistic regression.

Results

At the time of analysis, COVAD2 included 10,739 participants; 2007 had RA, 1997 with geographical data included in this study (mean age 50.9 years, 88.1% women). Most patients came from Europe (39.4%) and Asia (24.8%); 61.3% and 23.7% were from very high- and high-HDI countries, respectively. Overall, 29.6% of patients used advanced therapies, with the highest rate in Europe (44.0%), followed by North America and Oceania (33.9%), South America (31.1%), Asia (11.7%), and Africa (5.3%) (p < 0.001). Usage correlated strongly with HDI: 2.7% in low-HDI to 38.8% in very-high-HDI countries (Compared to very-high income, Odds Ratio for high 0.561 (95% CI 0.403;0.782), for medium 0.288 (95% CI 0.153;0.539), and for low income 0.275 (95% CI 0.034;2.199); p < 0.001). Regions with limited access relied more on glucocorticoids. Disparities across continents and HDI categories remained after adjusting for confounders(demographic characteristics, disease activity, comorbidities, and patient-reported outcomes.

Conclusion

Marked continent- and HDI-based inequities in biologic and targeted DMARD use persist globally, demanding coordinated action from the rheumatology community to ensure equitable RA care across resource settings.